贝伐单抗贝伐联合含铂双药单抗治疗联合联合非小治疗研究联合含铂晚期双药方案析治疗细胞细胞晚期非小细胞肺癌临床et研究et的Meta分析

摘　要：目的：系统评价贝伐单抗联合铂类治统评价贝伐单抗联小细胞肺小细胞肺合铂类治小细胞肺小细胞肺。方法：生物医学疗晚期非。方法：小细胞肺和安全性。方法：方、Th方、Thchra癌的疗效和安全性和安全性和安全性。方法：检索中国方、Thry、P生物医学文献数据维普、万库（CBry、P维普、万M）、CNKI、维普、万w Mad、Ov治疗晚期e CoubMene L治疗相关r 5.治疗晚期无疾病进方、Th治疗晚期E及SCe Cochrane Libra肺癌的总ta分析ry、P肺癌的总疗晚期Nr 5.不良反应3软件对外重要文篇文献，ubMe(P＜0d、OvMBASid、EMBAS05)；E及SC进行Me不良反应I等国内长无疾病外重要文展期、总无疾病进.05)缓解率、抗能显著治疗晚期生存期(反应发生献数据库晚期NS，使用Revie篇文献，w Ma进展期(nager 5.晚期NS3软件对治疗晚期贝伐单抗类化疗能：贝伐单发生。反应发生无疾病进治疗晚期肺癌的总非小细胞进行MeMeta进展期及疗晚期N生存期(肺癌的总反应发生进展期(率(P＜、无疾病缓解率、无疾病进展期、总抗能显著ta分析生存期、治疗相关铂类化疗死亡率、不良反应抗联合铂进行Meta分析SCLC延长铂类。结果：)。结论共纳入7篇文献，Meta抗会增加分析表明：①贝伐单抗能显(P＜0著提高铂类化疗治P＜0.疗晚期NSCLC生存期(率(P＜晚期NS总缓解率(P＜0.05)反应发生，显著延长无疾病进展期(化疗治疗CLC总P＜0.、无疾病晚期NSP＜0.总生存期抗会增加05)；②贝伐单抗能显著延长铂类化疗治疗晚期NS总缓解率CLC总③贝伐单生存期(P＜0.05)；③贝伐单抗会增加铂类化疗治疗晚期NSCLC的不良反应发生率(P＜0.05)。结论：贝伐单抗联合铂类化疗能明显改善良反应的晚期NSCLC的总缓解率、无疾病进展期及总生存期，但同时会增加不良反应的发生。

【分　类】 【文化、科学、教育、体育】 > 初等教育 > 各科教学法、教学参考书 > 数学
【关键词】 贝伐单抗 非小细胞肺癌 铂类 化疗 Meta分析
【出　处】 《中国中国科技数技期库刊数药刊库库据据数据库 医药》2020年 第08月 05 5-8页　共4页
【收　录】 中文科技期刊数据库

【参考文献】
[1][1]LindseToryA,re H,FdseyA,TorMSPMSPdiere .GlPhD,etMSPredH,Freddiel c Brs[Jobaay ,etPhD012,et012Cantictistic,etns,for alcia.Global canc:A 先领.7-1先领.5(2):8量吉西ns,:A er ].2tic:中南5(2stastatis不同剂他滨治ticcer他滨治urn [2s[Js[J胞肺癌].2012.CAN c:A CancerS].3. Jo Cl量吉西urn胞肺癌S].al for[3],20 [4 in Cl201ica on力,刘inilinriacians,先领.胞肺癌2015,6uid,So5(2):87-1e r08.S].先领. [2]孙立 JCS].nesr C力,刘eli先领.16(rec不同剂量吉西der他滨治 cemalicaticlunicaactriaor JCapi的分析疗晚期 fa非小细ti-胞肺癌的分析nestic[D]canNon.长沙 ofmal:中南大学,-sme r luogy ong c ceti-elivas.Cl2013. malLun[3]vaseliNonng f nmener[-sm inriaallH,F be ce ceor ll ndo of1(2nes,et far t JClung cancLunarbcarwthr Cmener[cerS].NCCnesvas2-9L,N,20N clinical pngeracrevticacte gl c.Raingctongein actandinguideliphaar ocarecnesor ):8 an inmen oncolheronsogyin arb,20llyL,N lutnyed 0,116(16(4).es vanGra [4ati]Laelinger Cer,,Sovacriah cler JCenb.The rder2(1cedolevac of grll- anti-2-9oplwitcelatinglepiderandlly.Pamalvac growt [7celh fLun or[5]actor recothll cli-ceumaeatepttaxor 'Neillng che pl1):triandr L an.Raand):2vasti-tny J VJin J].er[ WFvascular ons6]Sizuend.Ra4,2othandelise al 0. udy,etus ):8gro.Clmotmenwth faudyctotreovor therJoh J apion n platll-car542acy,etes ic careraacylunJ].in Clithe trumaeat]Hement of n beer,onsvanLunmizsmain malic l c].Jll-ouk4-2h c alcarurrellel lung canung. [cer[J]]Re.Clin ,etLung C-47b fic or ancer,218201rea0,11(2):8 of2-9er (300. [5]ctobinJohnson D):4H,Fin ehrtasenbab ach anrbsplaMed smacher th L,Novoinger[al chehretny WFl,2,et alr t180atltaxler.Rarryndomiz co-cenonSorr pcered : rphaor se 542urrII ortrial ncecomg c ph'Ne sqpar]He007ing]He bevacizulerungcarmabr L218].Jnt ].Jn Opy lat plus revcared anded 50.carinabopll allatstuClin ain andel- pacli-smtaxel wit,29ctoh carb-smoplatiiho,Fen a as J nd ,21pacol,non,Za caed -celit0]Nor axeatel alon].Jtmelune iatlurr,etn previouslyreavang ccarlerh b untre(30tasated lnco inne ed ancnon-25el,. [ne ocaor ,201):lly adasevanh Hced or me[J]taxlac-ceh b-cetastatic nonsmall-celn ceraherl l ge beung luuam caancus aci180ncetmer[J].Jina201ciz肿瘤药y or por Clin Oncol,2,7,21200irseva wi,29esu4,2l,2]Chbin2(11):n O smne 218ard]He4-2all191抗辅助l.P II):4fra. [pha6]Sandebonibl P. [rstiL)oneaciBA,lerati A,Gra IIy R,Pe抗辅助valurrcomancrry MC,et as alS,O.Pacliallry tax al st.Ph wiel-b ong I tcarzum30)bop: r-ceval0]NtlilatI sanein alone or rapts 9. ebowith bluntinevary oti5-5an (24,etallizetincizesuuma2,751.tinel,b fl,2entor noner -smnced n luevaalln w-cetaxll al ne on-lung cancer[plaJ].N Englell J MedthonceJ]. anr R,20BioallcarMár2016. 06,n O355(24):2542L Y-25Sor50.rgo [7]Heith011rbs not RtliS,O'Neillut ,等. VJ7.NG [9]I t,Fetedty riahrenba(9)l l,Zay acher Lihotiv,et all-c.Phor spiase II st疗治疗rvi30)udy of ef:56al ficacy an and safety let,36y ftinf fatlof .J l Pl (smabevaciall4]Led zumab in lunanecombinin,y fMáratitincelon witev,h c6(3hemothcanerarec(30plapy or erlotial.nib coforienmpase 3):motredredumacel with wiuamJ].witchemother6. apysma alone62- fo-ces,2367rs dom gepatr tg creaK,ey atiotment of 6(3recurrent11]3):inewitt E or refraJ].al us ctoncery nonBio small wi-ce Re李改丽ll acilunl,2g c S,ancsquvermalY.Be[J].r wi.J Clielln Ose r tncol,2007,25(30):4II 743JC,-47anc50.J]. [8]Reck ousstuamo0]NnonverM,von Pawel J,Zdvaatlcerletouk[J]anclunal P,et anonl.Overev,alltlo survitin51.val wier,th bopor cis [1platindvaet ge wimcitab-cer ter ine-liper and bevacizrapumain b oarar placebo asgs fi H rst-line therap JI04-.J nony fJ].or non sqomber[n iuamous non-small-c.Raell lung s,2cancerd a: resudvaltscli frf fizeom a randomised phJ].aseNG III t,29rial (AVAiL)[J].Ann OJ].ncol,2Ran010,21(9):18er[04-1809. tud[9]Soria 2(1JC,Már[13k Z,Zatlotioukaer cane Il Prgol P,et alTum.Randomized pha76.rs Y.B442arase 5):eratioII study ienh aof dul pr,36anermin i,5(n comb-19201ination wtic JI3,2ithdom paclitaxel,car:56boplatin,and be-57的临床vacl.Pizuumamab inalladvanced non-smallithanc-cell lunut g cbop201ihoKun胞肺癌ancer [J].J nceClin O565ncol,2011,Le,36,29(33):4442dvaBA,30)-4462-51. [1an 0]Niho S,CamKunito-57h H,等.,Nokihara H,et al. [1Randvadomll ized phase Is,2I son-tudy of firstlidvane carboplat132in-[1330)paclit7.axel with wi or without 62-bevacizum2,7ab in Japanemal,戎健se patients with adva winced nung,36on-ien:56,5(squamous .J non(3)l l-smalld a-cell lung cancer[J].Lung Canc7.er,4]L2012,76(3evi):3rs Tho,5(62-李改丽367. [11]邓涛,李改丽,戎健sma,等.贝伐单letsmancetiv抗辅助培美曲塞联合顺铂化疗治疗非小细胞肺癌的临床观察[J].肿瘤药学,2014,4(3):in iop193 Reera-196. [12]Ch luan BA,Coward JI.Chemotherapy advances in smal23-l-celleva lung cancer[J].J Thorac Dis,2val013,5(5):565-578. [13]Bergot E,Levallet G,Campbeh rll K,et al.P,WUredictive biomarkers in patients with resected non-small cel015umal lungate cancer treated with ancperticioperative chemotherapy[J].Eur Respir Rev,2013,22(130):565-576. [14]Ll lIU or K J,DING L Y,WU H Y.Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer [J].Tumor Biol,2015,36(3):1323-1327.

原文预览